Singulair (montelukast; Merck & Co/Kyorin) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Singulair" drug pipelines has been added to ResearchAndMarkets.com's offering.

Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.

1 Product Profiles

  • Singulair: Asthma

List of Figures

Figure 1: Singulair for asthma - SWOT analysis

Figure 2: The author's drug assessment summary of Singulair in asthma

Figure 3: The author's drug assessment summary of Singulair in asthma

Figure 4: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Singulair drug profile

Table 2: Singulair pivotal trial data in asthma

Table 3: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Companies Mentioned

  • Merck & Co
  • Kyorin

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r52x5b/singulair?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Asthma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Asthma Drugs